ConductScience.org, home

Trial · NCT04594369

Results by group91

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Annualized Rate of Pulmonary Exacerbations (PEs)Brensocatib 10 mg1.01595% Confidence Interval 0.910 to 1.132exacerbation per participant-year
Annualized Rate of Pulmonary Exacerbations (PEs)Brensocatib 25 mg1.03695% Confidence Interval 0.927 to 1.157exacerbation per participant-year
Annualized Rate of Pulmonary Exacerbations (PEs)Placebo1.28695% Confidence Interval 1.158 to 1.428exacerbation per participant-year
Time to First PEBrensocatib 10 mg49.00095% Confidence Interval 40.000 to NAweeks
Time to First PEBrensocatib 25 mg50.71495% Confidence Interval 37.571 to NAweeks
Time to First PEPlacebo36.71495% Confidence Interval 31.143 to 41.429weeks
Responder Status for Exacerbation-Free Over the 52-Week Treatment PeriodBrensocatib 10 mg48.5percentage of participants
Responder Status for Exacerbation-Free Over the 52-Week Treatment PeriodBrensocatib 25 mg48.5percentage of participants
Responder Status for Exacerbation-Free Over the 52-Week Treatment PeriodPlacebo40.3percentage of participants
Change From Baseline at Week 52 in Postbronchodilator Forced Expiratory Volume in 1 Second (FEV1)Brensocatib 10 mg-0.050Standard Error 0.0093liter (L)
Change From Baseline at Week 52 in Postbronchodilator Forced Expiratory Volume in 1 Second (FEV1)Brensocatib 25 mg-0.024Standard Error 0.0099liter (L)
Change From Baseline at Week 52 in Postbronchodilator Forced Expiratory Volume in 1 Second (FEV1)Placebo-0.062Standard Error 0.0094liter (L)
Annualized Rate of Severe PEsBrensocatib 10 mg0.13795% Confidence Interval 0.103 to 0.182exacerbation per participant-year
Annualized Rate of Severe PEsBrensocatib 25 mg0.13795% Confidence Interval 0.105 to 0.179exacerbation per participant-year
Annualized Rate of Severe PEsPlacebo0.18595% Confidence Interval 0.142 to 0.242exacerbation per participant-year
Change From Baseline at Week 52 in Quality of Life Questionnaire - Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score in Adult ParticipantsBrensocatib 10 mg6.841Standard Error 0.7706score on scale
Change From Baseline at Week 52 in Quality of Life Questionnaire - Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score in Adult ParticipantsBrensocatib 25 mg8.575Standard Error 0.7556score on scale
Change From Baseline at Week 52 in Quality of Life Questionnaire - Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score in Adult ParticipantsPlacebo4.809Standard Error 0.7500score on scale
Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Events (TEAEs)Brensocatib 10 mg452Participants
Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Events (TEAEs)Brensocatib 25 mg440Participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04594369/results